Abstract
Autoimmune diseases (AID) are caused by the loss of immunological tolerance against self-antigens. The deoxyribonuclease I (DNASE1) gene seems to participate in the genetic susceptibility of some AID. In fact, two mutations were reported among systemic lupus erythematosus (SLE) patients from Japan and Spain (the 172 A → T mutation (K5X) and the 46_72 deletion, respectively). The aim of our work was to evaluate the DNASE1 contribution in the genetic susceptibility of rheumatoid arthritis (RA, n = 151), Sjögren syndrome (SS, n = 55) and SLE (n = 34) in Tunisia. DNA from patients and healthy subjects (n = 232) were explored. Both reported mutations were absent among patient and control subjects. The DNASE1 exon2 sequence was analysed among 26 control subjects to identify new polymorphic variations that are possible. Five known SNPs were explored. The G/T transversion (rs8176927: R2S) was the most polymorphic functional nonsynonymous SNP. Using PCR-RFLP method, all DNAs were genotyped for rs8176927 for a case–control design. The statistical analysis showed no significant differences between patients and controls genotype data. In conclusion, our study showed, on the one hand, the absence of the K5X mutation and the 46_72 deletion in Tunisian patients affected with RA, SS and SLE and healthy subjects, and, on the other hand, the absence of association between the R2S polymorphism and the genetic susceptibility of RA, SS and SLE.
Similar content being viewed by others
Abbreviations
- AID:
-
Autoimmune diseases
- ANA:
-
Anti-nuclear antibodies
- DNASE1:
-
Deoxyribonuclease 1
- ds:
-
Double strand
- HETObs :
-
Observed heterozygosity
- PCR-RFLP:
-
Polymerase chain reaction-restriction fragment length polymorphism
- RA:
-
Rheumatoid arthritis
- SLE:
-
Systemic lupus erythematosus
- SNP:
-
Single nucleotide polymorphism
- SS:
-
Sjögren syndrome
References
Yasuda T, Awazu S, Sato W et al (1990) Human genetically polymorphic deoxyribonuclease: purification, characterization, and multiplicity of urine deoxyribonuclease I. J Biochem 108:393–398
Rauch F, Polzar B, Stephan H et al (1997) Androgen ablation leads to an upregulation and intranuclear accumulation of deoxyribonuclease I in rat prostate epithelial cells paralleling their apoptic elimination. J Cell Biol 137:909–923. doi:10.1083/jcb.137.4.909
Mannherz HG, Peitsch MC, Zanotti S et al (1995) A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 198:161–174
Lazarides E, Lindberg U (1974) Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci USA 71:4742–4746. doi:10.1073/pnas.71.12.4742
Carroll MC (1998) The lupus paradox. Nat Genet 19:3–4. doi:10.1038/ng0598-3
Rosen A, Casciola-Rosen L (1999) Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 6:6–12. doi:10.1038/sj.cdd.4400460
Hermann M, Voll RE, Kalden JR (2000) Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21:424–426. doi:10.1016/S0167-5699(00)01675-3
Tsukumo S, Yasutomo K (2004) DNaseI in pathogenesis of systemic lupus erythematosus. Clin Immunol 113:14–18. doi:10.1016/j.clim.2004.05.009
Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. doi:10.1002/art.1780400928
Wakeland EK, Liu K, Graham RR et al (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397–408. doi:10.1016/S1074-7613(01)00201-1
Ter Borg EJ, Horst G, Hummel EJ et al (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term prospective study. Arthritis Rheum 33:634–643. doi:10.1002/art.1780330505
Chitrabamrung S, Rubin RL, Tan EM (1981) Serum deoxyribonuclease 1 and clinical activities in systemic lupus erythematosus. Rheumatol Int 1:55–60. doi:10.1007/BF00541153
Macanovic M, Lachaman PJ (l997) Measurement of deoxyribonuclease 1 in the serum and urine of SLE-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 108:220–216. doi:10.1046/j.1365-2249.1997.3571249.x
Macanovic M, Sinicropi D, Shak S et al (1996) The treatment of systemic lupus erythematosus (SLE) in NZB/W F hybrid mice; studies with recombinant murine Dnase and with dexamenthasone. Clin Exp Immunol 106:243–252. doi:10.1046/j.1365-2249.1996.d01-839.x
Verthelyi D, Dybdal N, Elias KA et al (1998) DNAse treatment does not improve the survival of lupus prone (NZB/NZW) F mice. Lupus 7:223–230. doi:10.1191/096120398678920037
Yasutomo K, Horiuchi T, Kagami S et al (2001) Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28:313–314. doi:10.1038/91070
Simmonds MJ, Heward JM, Kelly MA et al (2002) A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves’ disease: comment on the article by Rood et al. Arthritis Rheum 46:3109–3110. doi:10.1002/art.10414
Chakraborty P, Hadj Kacem H, Makni-Karray K et al (2003) The A/T mutation in exon 2 of the DNASE1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects. Arthritis Rheum 48:3297–3298. doi:10.1002/art.11318
Liu MF, Wang CR, Fung LL (2004) No evidence of mutation in exon 2 of DNAse1 gene in Chinese patients with systemic lupus erythematosus. Lupus 13:142–143. doi:10.1191/0961203304lu478xx
Balada E, Ordi-Ros J, Hernanz S et al (2002) DNASE I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew et al. Arthritis Rheum 46:1974–1976. doi:10.1002/art.10349
Bodano A, Amarelo J, Gonzalez A et al (2004) Novel DNASE I mutations related to systemic lupus Erythematosus. Arthritis Rheum 50:4070–4073. doi:10.1002/art.20721
Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277. doi:10.1002/art.1780251101
Kaplan G (1991) Syndrome de Gougerot-Sjögren. In: Kahn MF, Peltier AP, Meyer O, Piette JC (eds) Les maladies systémique, 2nd edn. Flammarion Médecine-Sciences, Paris, pp 499–544
Arnett FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria fort he classification of rheumatoid arthritis. Arthritis Rheum 31:315–324. doi:10.1002/art.1780310302
Kawazaki E (1990) Sample preparation from blood, cells and other fluids. In: Innis M, Gelffand D, Snisky G, White T (eds) PCR protocols. A guide to methods and application, 2nd edn. Academic Press, San Diego, pp 146–152
Vyse TJ, Kotzin BL (1998) Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 16:261–292. doi:10.1146/annurev.immunol.16.1.261
Davis P, Percy JS, Russell AS (1977) Correlation between levels of DNA antibodies and clinical disease activity in SLE. Ann Rheum Dis 36:157–159. doi:10.1136/ard.36.2.157
Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359–366. doi:10.1136/ard.45.5.359
Benucci M, Saviola G, Baiardi P et al (2008) Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin Rheumatol 27:91–95. doi:10.1007/s10067-007-0728-5
Nardi N, Brito-Zerón P, Ramos-Casals M et al (2006) Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome, prevalence and clinical significance in 335 patients. Clin Rheumatol 25:341–346. doi:10.1007/s10067-005-0059-3
Rechlin M (1997) Systemic rheumatic diseases: undifferentiated connective tissue disease, overlap syndromes, and mixed connective tissue disease. In: Koopman WJ (ed) Arthritis and allied conditions a text book of rheumatology. William & Wilkins, Baltimore, pp 1445–1454
Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14:111–124. doi:10.1053/berh.1999.0080
Jablonska S, Blaszczyk M (1999) Scleroderma overlap syndromes. Adv Exp Med Biol 455:85–92
Naiperi M, Karsunky H, Zevnik B et al (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25:177–181. doi:10.1038/76032
Shin HD, Park BL, Kim LH et al (2004) Common DNase I polymorphism associated with autoantibody production among systemic lupus erythematosus patients. Hum Mol Genet 13:2343–2350. doi:10.1093/hmg/ddh275
Acknowledgments
This work was supported by the Ministère de l’enseignement supérieure de la Recherche Scientifique et de la Technologie (Tunisia) and the International Center for Genetic Engineering and Biotechnology (ICGEB) (Italy). We thank LGMH (Laboratoire de Génétique Moléculaire Humaine, faculté de Médecine de Sfax) members for the technical help. We are also very grateful for discussions with Dr. Saber Masmoudi.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Belguith-Maalej, S., Hadj-Kacem, H., Kaddour, N. et al. DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren syndrome and healthy subjects. Rheumatol Int 30, 69–74 (2009). https://doi.org/10.1007/s00296-009-0917-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0917-4